Abstract:Shao-Li Huang, 1– 3, &ast Hong-Yi Xin, 4, 5, &ast Xiao-Yan Wang, 4, 5, &ast Guang-Gui Feng, 3 Fu-Qing Wu, 3 Zhi-Peng Feng, 6 Zhou Xing, 2 Xi-He Zhang, 4, 5 Hong-Wu Xin, 4, 7, 8 Wen-Ying Luo 1 1 Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524400, People's Republic of China; 2 First Clinical College, Guangdong Medical University, Guangdong, 524400, People's Republic of China; 3 Clinical laboratory, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 4 Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 5 Guangdong Medical University Affiliated Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 6 Department of Gastroenterology, Yueyang Hospital Affiliated to Hunan Normal University, Yueyang, Hunan, 414000, People's Republic of China; 7 Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei, 434023, People's Republic of China; 8 Research Centre of Molecular Medicine, Medical College of Chifeng University, Chifeng, Inner Mongolian Autonomous Region, 024000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen-Ying Luo, Medical laboratory Center, Affiliated Hospital of Guangdong Medical University, 57th South Renmin Road, Zhanjiang, 524001, People's Republic of China, Tel +86 18312728748, Email Xi-He Zhang, Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China, Tel +86 19126491230, Email Venous thromboembolism is a condition that includes deep vein thrombosis and pulmonary embolism. It is the third most common cardiovascular disease behind acute coronary heart disease and stroke. Over the past few years, growing research suggests that venous thrombosis is also related to the immune system and inflammatory factors have been confirmed to be involved in venous thrombosis. The role of inflammation and inflammation-related biomarkers in cerebrovascular thrombotic disease is the subject of ongoing debate. P-selectin leads to platelet-monocyte aggregation and stimulates vascular inflammation and thrombosis. The dysregulation of miRNAs has also been reported in venous thrombosis, suggesting the involvement of miRNAs in the progression of venous thrombosis. Plasminogen activator inhibitor-1 (PAI-1) is a crucial component of the plasminogen-plasmin system, and elevated levels of PAI-1 in conjunction with advanced age are significant risk factors for thrombosis. In addition, it has been showed that one of the ways that neutrophils promote venous thrombosis is the formation of neutrophil extracellular traps (NETs). In recent years, the role of extracellular vesicles (EVs) in the occurrence and development of VTE has been continuously revealed. With the advancement of research technology, the complex regulatory role of EVs on the coagulation process has been gradually discovered. However, our understanding of the causes and consequences of these changes in venous thrombosis is still limited. Therefore, we review our current understanding the molecular mechanisms of venous thrombosis and the related clinical trials, which is crucial for the future treatment of venous thrombosis. Keywords: venous thromboembolism, miRNA, neutrophil extracellular traps, plasminogen activator inhibitor-1, EVs, inflammatory factor Venous thromboembolism (VTE) is a multifaceted, potentially fatal event that activates coagulation and fibrinolysis. 1 It is a condition that includes pulmonary embolism (PE) and deep vein thrombosis (DVT). 2 In addition, it is also the third most prevalent cardiovascular disease after stroke and coronary heart disease (CHD). 3 Venous thrombosis (VT) is a leading cause of mortality as well as morbidity worldwide, occurring in approximately one case in 1000 people per year in affluent nations. 4 DVT is the thrombosis that blocks the deep venous cavity, disrupting the venous reflux network and resulting in chronic deep venous dysfunction. 5,6 Furthermore, DVT is a consequence of a complicated interaction between enzymes and cellular processes, in which the endothelium, platelets, and leukocytes coordinate a pro-inflammatory state that ultimately leads to the clot formation 7 with higher mortality rate for acute DVT. 8 To date, vascular ultrasound and digital subtraction angiography are the primary techniques for diagno -Abstract Truncated-

Therapeutic implication of MicroRNA-320a antagonist in attenuating blood clots formed during venous thrombosis

Downregulation of Interleukin-6 and C-reactive Protein Underlies a Novel Inhibitory Role of Microrna-136-5p in Acute Lower Extremity Deep Vein Thrombosis

Advances in microRNA regulation of deep vein thrombosis through venous vascular endothelial cells (Review)

MiR-497-5p Ameliorates Deep Venous Thrombosis by Facilitating Endothelial Progenitor Cell Migration and Angiogenesis by Regulating LITAF

Role and Mechanism of Mir-5189-3p in Deep Vein Thrombosis of Lower Extremities

Exploration on the effect of anserine on the alleviation of DVT and its molecular mechanism

MiR-128-3p promotes the progression of deep venous thrombosis through binding SIRT1

Changes in Levels of Mir-374A-5p and IL-10 in Peripheral Blood of DVT Patients and the Relationship Between Them

miR-10b-5p regulates venous endothelial cells in deep venous thrombosis by targeting MFG-E8

Retracted: Effects of Microrna‐330 on Vulnerable Atherosclerotic Plaques Formation and Vascular Endothelial Cell Proliferation Through the WNT Signaling Pathway in Acute Coronary Syndrome

miR-150 regulates endothelial progenitor cell differentiation via Akt and promotes thrombus resolution

Upregulation of Mir-483-3p Contributes to Endothelial Progenitor Cells Dysfunction in Deep Vein Thrombosis Patients Via SRF.

Targeted microbubbles combined with low-power focused ultrasound promote the thrombolysis of acute deep vein thrombosis

Panel of Regulatory miRNAs for Blood Coagulation under Normoxic and Hypoxic Conditions

Poly (β-amino esters)/Mobil Composition of Matter 41-mediated delivery of siIL-1β alleviates deep vein thrombosis in rat hind limbs

Significant role of long non-coding RNA MALAT1 in deep vein thrombosis via the regulation of vascular endothelial cell physiology through the microRNA-383-5p/BCL2L11 axis

Sonothrombolysis Using Microfluidically Produced Microbubbles in a Murine Model of Deep Vein Thrombosis

Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism

Expression and Role of Interleukin‑1β and Associated Biomarkers in Deep Vein Thrombosis

ET1 acts as a potential plasma biomarker and therapeutic target in deep venous thrombosis rat model

Mir-21 Induces Endothelial Progenitor Cells Proliferation and Angiogenesis Via Targeting FASLG and is a Potential Prognostic Marker in Deep Venous Thrombosis